1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
PharmGen Science, Inc.

PharmGen Science, Inc.

KKRX:004720
2,775.00
KRW
-10.00
(-0.36%)
-6,087.64EPS
63.98BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
4,941.16
5,583.62
6,808.2
7,543.91
7,305.34
7,777.48
8,191.25
7,071.5
7,465.19
9,690.12
10,244.12
9,444.38
9,282.68
8,347.46
Basic EPS, GAAP
-468.94
-579
233
364
395
390
26
675
2,206
4,498
374
153.88
-6,256
-6,395.89
Free Cash Flow per Basic Share
-567.95
-306.69
319.26
455.47
11.89
282.63
-366.74
-204.05
-1,782.03
-850.2
131.89
-22.01
142.15
630.39
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
3,017.74
2,490.6
3,059.4
3,639.6
4,532.82
4,922.05
4,818.24
5,693.27
8,355.98
13,118.31
12,971.86
13,736.1
6,676.71
6,390.82
Tangible Book Value per Share
2,911.88
2,400.02
2,985.94
3,542.97
4,439.57
4,826.26
4,728.45
5,561.28
8,064.1
12,727.05
12,614.53
13,343.28
6,366.26
6,064.39
Basic Weighted Avg Shares
8
8
9
9
11
11
12
14
15
16
16
18
19
21
Sales/Revenue/Turnover
38,971
44,203
60,405
71,546
79,894
89,102
95,138
96,614
109,866
150,931
166,779
171,287
173,073
175,361
Operating Margin (%)
-8.8
-8.17
7.49
6.76
7.52
5.6
1.26
-0.47
-4.49
4.96
5.47
6.21
3.46
2.39
Depreciation Expense
1,041
914
821
759
1,130
1,227
2,322
2,963
3,142
3,371
4,247
4,636
4,560
4,693
Net Income, GAAP
-3,699
-4,584
2,067
3,452
4,320
4,468
302
9,222
32,466
70,060
6,089
2,791
-116,641
-134,363
Effective Tax Rate (%)
- -
- -
2.32
22.91
27.07
- -
41.61
18.6
22.73
22.12
27.94
- -
- -
- -
Profit Margin (%)
-9.49
-10.37
3.42
4.83
5.41
5.01
0.32
9.55
29.55
46.42
3.65
1.63
-67.39
-76.62
Working Capital
18,627
16,114
25,392
31,234
45,236
47,987
20,275
37,213
6,257
2,356
32,155
45,286
62,387
64,372
LT Debt
236
234
233
231
229
206
1,427
1,017
578
490
532
350
178
352
Total Equity
23,834
20,116
28,658
36,408
51,054
56,848
56,246
83,570
126,932
207,116
232,972
249,428
146,304
140,039
Return on Invested Capital (%)
- -
- -
16.36
10.2
9.38
- -
0.95
-0.64
-2.91
2.84
2.59
- -
- -
- -
Return on Capital (%)
- -
- -
8.64
9.6
8.77
- -
1.62
10.56
24.18
34.54
3.54
- -
- -
- -
Return on Common Equity (%)
-14.88
-20.81
8.45
10.6
9.88
8.3
0.54
13.21
30.85
41.94
2.77
1.16
-58.95
-69.72

Capital Structure

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
5,822
5,845
347
LT Borrowings
- -
- -
- -
LT Finance Leases
178
299
352
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
91,047
80,310
63,985

Working Capital

KRW

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
96,065
92,446
92,004
Cash, Cash Equivalents & STI
22,414
18,939
20,052
Accounts Receivable, Net
44,028
43,501
45,513
Inventories
28,470
28,512
25,360
Total Current Liabilities
33,679
31,839
27,632
Payables & Accruals
- -
- -
- -
ST Debt
5,822
5,845
347
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
21.94%
18.65%
-41.34%
Free Cash Flow
187.2%
-41.48%
-763.83%
Net Income, GAAP
-110.09%
-811.42%
-4,279.46%
Sales/Revenue/Turnover
11.53%
13.07%
1.04%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
42,506
42,901
41,653
44,227
171,287
2025
42,877
45,874
41,505
42,816
173,073
2026
43,323
47,717
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
107
58
-216
204.03
153.88
2025
-39.92
213
-126
-5,362.83
-6,256
2026
-45.08
-614
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Hee-Deok Park
Full Time Employees
229
Sector
Health technology
Industry
Pharmaceuticals: other
Address
50, Jeyakgongdan 2-gil Hwaseong-si GY South Korea 18622
IPO Date
Jun 15, 1990
Website
pharmgenscience.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
PharmGen Science, Inc. (004720.KS) develops and manufactures active pharmaceutical ingredients (APIs), key starting materials (KSMs), and advanced intermediates for the global pharmaceutical industry; its core offerings include generic APIs for cardiovascular, antidiabetic, antiviral, and oncology drugs, along with contract development and manufacturing organization (CDMO) services for custom synthesis and process optimization. The company operates primarily in South Korea, with exports to North America, Europe, and Asia, targeting generic drug manufacturers and multinational pharmaceutical firms. Founded in 2004 and headquartered in Seongnam-si, Gyeonggi-do, South Korea, PharmGen Science focuses on high-potency and complex molecule production through its specialized facilities compliant with cGMP standards. In recent developments, the company expanded its production capacity in 2024 through a new API manufacturing line investment and formed a strategic partnership with a leading Indian generic producer for joint API commercialization in 2025; additionally, it launched two novel intermediates for GLP-1 receptor agonists amid rising demand for diabetes treatments.